These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 27467910)

  • 1. HLA ligandomics identifies histone deacetylase 1 as target for ovarian cancer immunotherapy.
    Peper JK; Bösmüller HC; Schuster H; Gückel B; Hörzer H; Roehle K; Schäfer R; Wagner P; Rammensee HG; Stevanović S; Fend F; Staebler A
    Oncoimmunology; 2016 May; 5(5):e1065369. PubMed ID: 27467910
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A combined approach of human leukocyte antigen ligandomics and immunogenicity analysis to improve peptide-based cancer immunotherapy.
    Peper JK; Stevanović S
    Cancer Immunol Immunother; 2015 Oct; 64(10):1295-303. PubMed ID: 25822767
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Integrative -omics and HLA-ligandomics analysis to identify novel drug targets for ccRCC immunotherapy.
    Reustle A; Di Marco M; Meyerhoff C; Nelde A; Walz JS; Winter S; Kandabarau S; Büttner F; Haag M; Backert L; Kowalewski DJ; Rausch S; Hennenlotter J; Stühler V; Scharpf M; Fend F; Stenzl A; Rammensee HG; Bedke J; Stevanović S; Schwab M; Schaeffeler E
    Genome Med; 2020 Mar; 12(1):32. PubMed ID: 32228647
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prognostic value of tumor PD-L1 expression combined with CD8
    Wang Q; Lou W; Di W; Wu X
    Int Immunopharmacol; 2017 Nov; 52():7-14. PubMed ID: 28846888
    [TBL] [Abstract][Full Text] [Related]  

  • 5. HLA ligandome analysis identifies the underlying specificities of spontaneous antileukemia immune responses in chronic lymphocytic leukemia (CLL).
    Kowalewski DJ; Schuster H; Backert L; Berlin C; Kahn S; Kanz L; Salih HR; Rammensee HG; Stevanovic S; Stickel JS
    Proc Natl Acad Sci U S A; 2015 Jan; 112(2):E166-75. PubMed ID: 25548167
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Induction of human tumor-associated differentially expressed gene-12 (TADG-12/TMPRSS3)-specific cytotoxic T lymphocytes in human lymphocyte antigen-A2.1-positive healthy donors and patients with advanced ovarian cancer.
    Bellone S; Anfossi S; O'Brien TJ; Cannon MJ; Silasi DA; Azodi M; Schwartz PE; Rutherford TJ; Pecorelli S; Santin AD
    Cancer; 2009 Feb; 115(4):800-11. PubMed ID: 19117353
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Tumor-infiltrating lymphocytes expressing the tissue resident memory marker CD103 are associated with increased survival in high-grade serous ovarian cancer.
    Webb JR; Milne K; Watson P; Deleeuw RJ; Nelson BH
    Clin Cancer Res; 2014 Jan; 20(2):434-44. PubMed ID: 24190978
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phenotypic and Functional Analyses of B7S1 in Ovarian Cancer.
    Cai D; Wang F; Wang C; Jin L
    Front Mol Biosci; 2021; 8():686803. PubMed ID: 34307455
    [No Abstract]   [Full Text] [Related]  

  • 9. Stromal PD-L1-Positive Regulatory T cells and PD-1-Positive CD8-Positive T cells Define the Response of Different Subsets of Non-Small Cell Lung Cancer to PD-1/PD-L1 Blockade Immunotherapy.
    Wu SP; Liao RQ; Tu HY; Wang WJ; Dong ZY; Huang SM; Guo WB; Gou LY; Sun HW; Zhang Q; Xie Z; Yan LX; Su J; Yang JJ; Zhong WZ; Zhang XC; Wu YL
    J Thorac Oncol; 2018 Apr; 13(4):521-532. PubMed ID: 29269008
    [TBL] [Abstract][Full Text] [Related]  

  • 10. HLA-DR Presentation of the Tumor Antigen MSLN Associates with Clinical Outcome of Ovarian Cancer Patients.
    Tegeler CM; Scheid J; Rammensee HG; Salih HR; Walz JS; Heitmann JS; Nelde A
    Cancers (Basel); 2022 Apr; 14(9):. PubMed ID: 35565389
    [TBL] [Abstract][Full Text] [Related]  

  • 11. HLA ligandome analysis of primary chronic lymphocytic leukemia (CLL) cells under lenalidomide treatment confirms the suitability of lenalidomide for combination with T-cell-based immunotherapy.
    Nelde A; Kowalewski DJ; Backert L; Schuster H; Werner JO; Klein R; Kohlbacher O; Kanz L; Salih HR; Rammensee HG; Stevanović S; Walz JS
    Oncoimmunology; 2018; 7(4):e1316438. PubMed ID: 29632711
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Association of ovarian tumor epithelium coexpressing HLA-DR and CA-125 antigens with tumor infiltrating cytotoxic T lymphocytes.
    Matsushita N; Ghazizadeh M; Konishi H; Araki T
    J Nippon Med Sch; 2003 Feb; 70(1):40-4. PubMed ID: 12646975
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Melanocortin 1 Receptor-derived peptides are efficiently recognized by cytotoxic T lymphocytes from melanoma patients.
    González FE; Ramírez M; Allerbring EB; Fasching N; Lundqvist A; Poschke I; Achour A; Salazar-Onfray F
    Immunobiology; 2014 Mar; 219(3):189-97. PubMed ID: 24192537
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The prognostic value of tumor-infiltrating T lymphocytes in ovarian cancer.
    Li J; Wang J; Chen R; Bai Y; Lu X
    Oncotarget; 2017 Feb; 8(9):15621-15631. PubMed ID: 28152503
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Identification of a naturally processed HLA-A*0201 HPV18 E7 T cell epitope by tumor cell mediated in vitro vaccination.
    Kather A; Ferrara A; Nonn M; Schinz M; Nieland J; Schneider A; Dürst M; Kaufmann AM
    Int J Cancer; 2003 Apr; 104(3):345-53. PubMed ID: 12569558
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The natural HLA ligandome of glioblastoma stem-like cells: antigen discovery for T cell-based immunotherapy.
    Neidert MC; Kowalewski DJ; Silginer M; Kapolou K; Backert L; Freudenmann LK; Peper JK; Marcu A; Wang SS; Walz JS; Wolpert F; Rammensee HG; Henschler R; Lamszus K; Westphal M; Roth P; Regli L; Stevanović S; Weller M; Eisele G
    Acta Neuropathol; 2018 Jun; 135(6):923-938. PubMed ID: 29557506
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Identification of two HLA-A*0201 immunogenic epitopes of lactate dehydrogenase C (LDHC): potential novel targets for cancer immunotherapy.
    Thomas R; Shaath H; Naik A; Toor SM; Elkord E; Decock J
    Cancer Immunol Immunother; 2020 Mar; 69(3):449-463. PubMed ID: 31932876
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Siglec-7 is a predictive biomarker for the efficacy of cancer vaccination against metastatic colorectal cancer.
    Yamada K; Hazama S; Suzuki N; Xu M; Nakagami Y; Fujiwara N; Tsunedomi R; Yoshida S; Tomochika S; Matsukuma S; Matsui H; Tokumitsu Y; Kanekiyo S; Shindo Y; Watanabe Y; Iida M; Takeda S; Ioka T; Ueno T; Ogihara H; Hamamoto Y; Hoshii Y; Kawano H; Fujita T; Kawakami Y; Nagano H
    Oncol Lett; 2021 Jan; 21(1):10. PubMed ID: 33240416
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prognostic impact of programmed cell death-1 (PD-1) and PD-ligand 1 (PD-L1) expression in cancer cells and tumor-infiltrating lymphocytes in ovarian high grade serous carcinoma.
    Darb-Esfahani S; Kunze CA; Kulbe H; Sehouli J; Wienert S; Lindner J; Budczies J; Bockmayr M; Dietel M; Denkert C; Braicu I; Jöhrens K
    Oncotarget; 2016 Jan; 7(2):1486-99. PubMed ID: 26625204
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Systematic evaluation of multiple immune markers reveals prognostic factors in ovarian cancer.
    Santoiemma PP; Reyes C; Wang LP; McLane MW; Feldman MD; Tanyi JL; Powell DJ
    Gynecol Oncol; 2016 Oct; 143(1):120-127. PubMed ID: 27470997
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.